Section 01
What it's used for
Stroke trial did not meet its goal
In a trial of 1,070 stroke patients, this peptide mixture did not beat placebo on its main outcome, though a severe-stroke subgroup trended toward fewer deaths. A 2017 review of 7 trials (1,779 patients) found no significant benefit.
▸Clinical wording
The CASTA trial (n=1,070: 529 on Cerebrolysin, 541 on placebo) in acute ischemic stroke did not meet its primary combined endpoint (NIHSS, modified Rankin Scale, and Barthel Index) versus placebo; a post-hoc subgroup of more severe strokes (NIHSS>12) showed a mortality trend favoring Cerebrolysin. A 2017 meta-analysis of 7 randomized controlled trials (1,779 patients) likewise found no significant benefit on modified Rankin Scale or Barthel Index and concluded that routine use of Cerebrolysin for acute ischemic stroke could not be supported by available evidence.
Modest help in mild Alzheimer's
Reviews of clinical trials from 2007 and 2015 found modest gains in thinking skills in people with mild-to-moderate Alzheimer's disease. Note: a widely cited 2019 Cochrane review actually covers vascular dementia, a different condition.
▸Clinical wording
Meta-analyses of randomized controlled trials from 2007 and 2015 (not Cochrane reviews) found modest cognitive improvement with Cerebrolysin in mild-to-moderate Alzheimer's disease. No 2019 Cochrane review of Cerebrolysin for Alzheimer's disease exists; the only 2019 Cochrane review of Cerebrolysin, by Cui et al., covers vascular dementia, a different indication. Most of the underlying trials were conducted in Europe and Asia.
Studied for brain injury recovery
Clinical studies in people with traumatic brain injury found improved recovery of thinking and memory skills, called cognitive recovery, plus reduced disability. Researchers observed these benefits, though no trial size or dose is stated.
▸Clinical wording
Clinical studies show improved cognitive recovery and reduced disability.
Studied for vascular dementia
Evidence from clinical studies in people with vascular dementia — dementia caused by reduced blood flow to the brain — points to improved cognitive function: better thinking, memory and mental processing in this patient group.
▸Clinical wording
Evidence for improved cognitive function in vascular dementia patients.
Section 02
Mechanism of Action
Prompting the brain's own growth factors
- In injured mouse nerve-tumour cells, the preparation raised the cells' own nerve growth factor messengers.
- So part of the effect is inducing home-made growth factors rather than delivering them.
- In rats treated a day after stroke, new brain cells and remodelled nerve fibres increased.
- Blocking the Sonic hedgehog pathway abolished those regenerative effects in culture.
▸Clinical wording
Sonic hedgehog signalling and endogenous neurotrophin output
In Neuro-2A mouse neuroblastoma cells injured with tert-butyl hydroperoxide, Cerebrolysin at 0.2 µg/mL raised BDNF and neuregulin-1 mRNA above injury-only controls, so part of the trophic profile reflects induction of the cell's own neurotrophins rather than delivery of them (Anandan 2024). The regenerative response in vivo appears to route through Sonic hedgehog: rats treated 24 h after embolic stroke showed increased subventricular-zone progenitor proliferation, neurogenesis, oligodendrogenesis and axonal remodelling in peri-infarct tissue, and blocking the pathway with cyclopamine abolished cerebrolysin-induced neurogenesis and oligodendrogenesis in vitro (Zhang 2013).
Blocking an enzyme that eats nerve scaffolding
- An overactive enzyme degrades nerve cell scaffolding during stroke and Alzheimer-type damage.
- In cell-free assays the preparation inhibited both forms of that enzyme, across three assay types.
- The inhibition reversed on dialysis and was credited to natural inhibitor fragments in the preparation.
- These are enzyme-level laboratory observations, not clinical endpoints.
▸Clinical wording
Calpain inhibition and cytoskeletal protein preservation
Overactivated calpain degrades neuronal cytoskeletal proteins during ischaemia and in Alzheimer-type pathology. In cell-free assays Cerebrolysin inhibited both µ- and m-calpain, shown by a caseinolytic assay, by a synthetic fluorogenic peptide substrate and by a fluorimetric assay using DTAF-labelled MAP2, with kinetics fitting a non-competitive or tight-binding competitive mode. Dialysis showed the inhibition was reversible, and the authors attributed it to calpastatin or calpastatin-like fragments carried in the preparation (Wronski 2000). These are enzyme-level in vitro observations, not clinical endpoints.
Less inflammation and swelling after head injury
- In mice with a weight-drop head injury, treatment lowered two immune sensors and several inflammatory messengers.
- Reactive oxygen species fell and a tight-junction protein rose alongside less brain swelling.
- Cell-death proteins fell, a survival protein rose, and fewer hippocampal neurons were dying.
- The authors tie the anti-swelling effect to junction proteins rather than a direct vascular action.
▸Clinical wording
TLR2/TLR4 signalling, neuroinflammation and barrier integrity
In C57BL/6J mice given a Feeney weight-drop traumatic brain injury, intraperitoneal Cerebrolysin over 72 h lowered TLR2 and TLR4 expression together with NF-κB, TNF-α, IL-1β and IL-6, and reduced reactive oxygen species measured by DCF-DA. Zonula occludens-1 rose alongside less brain oedema, while cleaved caspase-3 and Bax fell, Bcl-2 rose, and fewer hippocampal neurons were TUNEL-positive (Lu 2022). The study ties the anti-oedema effect to tight-junction protein expression rather than to a direct vascular action.
More glucose crossing into the brain
- Glucose enters the brain through a transporter on the lining cells of the barrier.
- In rats, the preparation raised glucose transfer into the brain 1.6 to 1.9 times.
- Transporter protein rose in parallel on two independent detection methods.
- In cultured barrier cells the rise happened after the gene was read, not at transcription.
▸Clinical wording
Blood-brain barrier GLUT1 glucose transport
Glucose entry into brain depends on the GLUT1 transporter of the barrier endothelium. In Wistar rats, acute or chronic Cerebrolysin raised the brain permeability-surface area product for D-[14C]glucose 1.6- to 1.9-fold, with parallel increases in GLUT1 protein on Western blot and immunocytochemistry (Boado 1999). In cultured brain endothelial (ECL) cells the effect was post-transcriptional: reporter constructs carrying GLUT1 translational-control and mRNA-stabilising elements were induced dose-dependently, and GLUT1 protein and glucose uptake both rose (Boado 2001).
Less amyloid in one mouse model
- In amyloid-model mice treated for six months, maze learning improved and amyloid burden fell.
- Levels of the amyloid parent protein and its cut fragments dropped.
- The enzymes that cut or clear amyloid were unchanged, so processing and trafficking shifted instead.
- This whole line of evidence rests on a single transgenic mouse model.
▸Clinical wording
Amyloid precursor protein maturation and proline-directed kinases
In APP transgenic mice treated for 6 months, Cerebrolysin improved spatial-learning performance in the water maze and reduced synaptic pathology and amyloid burden. Immunoblot and confocal analysis showed lower full-length APP and APP C-terminal fragments while BACE1, Notch1, neprilysin and insulin-degrading enzyme were unchanged, so the amyloid effect tracked with APP maturation and trafficking rather than with secretase or degradation capacity; APP phosphorylation fell alongside reduced CDK5 and GSK-3β activity (Rockenstein 2006). This line rests on a single transgenic mouse model.
Section 03
Biological Pathways
- Sonic hedgehog and neurotrophinsIn injured Neuro-2A cells Cerebrolysin raised BDNF and neuregulin-1 mRNA; after embolic stroke in rats it increased neurogenesis via Sonic hedgehog signaling, blocked by cyclopamine in vitro.
- Calpain inhibitionIn cell-free assays Cerebrolysin reversibly inhibited both mu- and m-calpain in caseinolytic, fluorogenic-substrate and DTAF-MAP2 assays, an activity attributed to calpastatin-like fragments in the preparation.
- TLR2/TLR4 and neuroinflammationAfter weight-drop brain injury in mice, Cerebrolysin lowered TLR2, TLR4, NF-kB, TNF-alpha, IL-1beta and IL-6, raised zonula occludens-1 with less oedema, and reduced TUNEL-positive neurons and caspase-3.
- GLUT1 barrier glucose transportIn rats, Cerebrolysin raised brain glucose permeability 1.6 to 1.9 fold with parallel GLUT1 protein increases; in cultured brain endothelial cells the effect was post-transcriptional, inducing GLUT1 translation.
- APP maturation and kinase activityIn APP transgenic mice treated for 6 months, Cerebrolysin lowered full-length APP and its C-terminal fragments with reduced CDK5 and GSK-3beta activity, while BACE1, Notch1 and neprilysin stayed unchanged.
Section 04
Dosage Information
Complex mixture of neuropeptides and amino acids (MW < 10 kDa)| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Intravenous drip — acute stroke | Label in Austria, Germany, Russia, China; not the FDA | 10–50 mL a day in the acute phase, 5–30 mL in recovery, daily for 10–20 days. Trials clustered at 30 mL for 10 days. | Seven trials, 1773 patients: no clear difference in deaths, and serious non-fatal harms more than doubled — RR 2.87 at that same 30 mL, 10-day schedule. |
| Intravenous drip — dementia and memory | Label uses; Cochrane pooled 6 trials, 597 patients | 5–30 mL a day for memory problems, 10–30 mL for Alzheimer's, 5–20 mL for poor brain blood flow; 10–20 days, repeated every 3–6 months. | All six trials risked bias and the evidence was very low quality; Cochrane called the gain it found, 0.36 standard deviations, possibly too small to matter. |
| Into muscle or slowly into a vein | Label ceilings for undiluted injection | Up to 5 mL into muscle, up to 10 mL into a vein, undiluted; more must be diluted to 100 mL and dripped in over 15–60 minutes. | A volume ceiling, not a dose: 5 mL into muscle is a sixth of the 30 mL the stroke trials gave, and the label offers no longer course to make it up. |
| Into a vein or muscle — children | Label, developmental delay and ADHD in under-18s | 0.1–0.2 mL/kg a day. The same ratio at 70–90 kg would be 7–18 mL, but the label sets adult doses by condition, not by weight. | The children's uses are developmental and behavioural; both Cochrane reviews cover adult stroke and adult dementia, so neither speaks to this dose. |
Section 05
Protocols
No protocols featuring this peptide yet. Browse All Protocols
Section 06
Stability & Storage
Storing the product
Cerebrolysin is supplied as an aqueous solution (215.2 mg/mL) in ampoules, with a shelf life of 5 years. Ampoules are kept at room temperature, up to 25°C, and protected from light. The solution is intended for intravenous administration after dilution in saline.
After opening
Ampoules are single-dose containers, so the solution is used at the time it is opened rather than stored afterwards. Once diluted in saline for intravenous use, the resulting preparation is administered rather than kept for later use. Any unused portion of an opened ampoule is discarded rather than resealed.
Section 07
Side Effects & Precautions
Dizziness (7%), headache, nausea, injection site reactions. Fever and agitation rarely. Generally well-tolerated in large clinical trials. Contraindicated in epilepsy and severe renal impairment.
Section 08
Regulatory Status
FDA / United States
Not approved
No New Drug Application for Cerebrolysin has been approved in the US. Several Phase III stroke trials (CARS, CARS-NHI, CASTA) produced data both FDA and Cochrane reviewers judged insufficient to establish a clear clinical benefit, and it remains unavailable outside clinical trials.
European Union
No EU-wide authorisation
The EMA has not granted Cerebrolysin a centralised marketing authorisation; wherever it is sold inside the EU, that rests on a national registration, not a single Europe-wide review.
Austria
Registered prescription medicine
Manufacturer EVER Neuro Pharma holds a national Austrian marketing authorisation (BASG/AGES registration No. 1-21380) for the injectable solution, dispensed by prescription and given by IV or IM injection.
Russia, China & elsewhere
Registered in 50+ countries
National health authorities in Russia, China and dozens of other countries across Eastern Europe, Asia and Latin America have separately registered Cerebrolysin as a prescription drug for stroke, traumatic brain injury and dementia-spectrum indications — each under its own review, not a shared standard.
"Registered" describes dozens of separate national decisions, not one global approval, and it says nothing about FDA or EMA review specifically. Regulatory status differs by country and changes over time — check the current rules where you are.
Section 09
Research Studies
- [1]Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after strokeZhang L, Chopp M, Meier DH, et al. · Stroke · 2013
- [2]Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpainWronski R, Tompa P, Hutter-Paier B, et al. · Journal of Neural Transmission · 2000
- [3]Cerebrolysin alleviates early brain injury after traumatic brain injury by inhibiting neuroinflammation and apoptosis via TLR signaling pathwayLu W, Zhu Z, Shi D, et al. · Acta Cirurgica Brasileira · 2022
- [4]In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptidesBoado RJ, Wu D, Windisch M. · Neuroscience Research · 1999
- [5]Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptidesBoado RJ. · Neuroscience Research · 2001
- [6]Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's diseaseRockenstein E, Torrance M, Mante M, et al. · Journal of Neuroscience Research · 2006
- [7]Neuroprotection by Cerebrolysin and Citicoline Through the Upregulation of Brain-Derived Neurotrophic Factor (BDNF) Expression in the Affected Neural Cells: A Preliminary Clue Obtained Through an In Vitro StudyAnandan P, Rengarajan S, Venkatachalam S, et al. · Cureus · 2024
Section 10
Frequently Asked Questions
The largest trial, CASTA (1,070 patients), did not meet its primary endpoint against placebo; a subgroup with more severe strokes showed a mortality trend favouring Cerebrolysin, but that was a secondary finding, not the main result. A 2017 meta-analysis of seven trials (1,779 patients) likewise found no significant benefit on standard disability scales and concluded routine use in acute ischemic stroke isn't supported by the evidence — and in that same pooled data, serious non-fatal harms were more than doubled (RR 2.87) at the commonly used 30 mL/10-day schedule.
Meta-analyses from 2007 and 2015 found modest cognitive improvement in mild-to-moderate Alzheimer's disease. A separate 2019 Cochrane review pooling six trials in vascular dementia (597 patients) found a gain of 0.36 standard deviations that the reviewers called possibly too small to matter clinically, rating all six trials as at risk of bias with very low-quality evidence overall. Note that this 2019 Cochrane review covers vascular dementia, not Alzheimer's — no 2019 Cochrane review of Cerebrolysin for Alzheimer's disease exists, a distinction that sometimes gets blurred online.
Reported effects include dizziness (about 7%), headache, nausea and injection-site reactions, with fever and agitation occurring rarely. It is generally described as well tolerated in large trials, but it is contraindicated in epilepsy and severe kidney impairment.
It is approved and used clinically in more than 50 countries across Europe, Asia and Latin America, but it has never gone through FDA approval and is not sold in the US. The material doesn't state the FDA's specific reasoning, but it does note that the pivotal stroke trial (CASTA) failed its primary efficacy endpoint and that a later meta-analysis found more than double the serious non-fatal harm at standard dosing, either of which would work against an approval case.
For acute stroke, trials most often used 30 mL a day by IV drip for 10 days; dementia protocols used 5-30 mL a day for 10-20 days, repeated every 3-6 months. It doesn't need refrigeration before use — ampoules are kept at room temperature (up to 25°C) protected from light, with a 5-year shelf life — but each ampoule is single-dose: once opened or diluted for infusion, it's used immediately and any unused portion is discarded.
Available trial courses run 10-20 days, repeated every 3-6 months, rather than continuous daily use — the material doesn't describe a study of true long-term daily dosing beyond those repeated courses. It is contraindicated in epilepsy and severe renal impairment.
One small study looked at the two together rather than head-to-head: Cerebrolysin combined with citicoline increased BDNF expression in affected neural cells in a preliminary cell-culture experiment. The available material doesn't include a direct clinical comparison of the two as standalone treatments, so there's no finding on which works better or whether they're interchangeable.